Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Free Cash Flow (2021 - 2025)

Verrica Pharmaceuticals has reported Free Cash Flow over the past 5 years, most recently at -$4.6 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$4.6 million for Q4 2025, up 71.2% from a year ago — trailing twelve months through Dec 2025 was -$17.6 million (up 71.08% YoY), and the annual figure for FY2025 was -$17.6 million, up 71.08%.
  • Free Cash Flow for Q4 2025 was -$4.6 million at Verrica Pharmaceuticals, down from $9.7 million in the prior quarter.
  • Over the last five years, Free Cash Flow for VRCA hit a ceiling of $9.7 million in Q3 2025 and a floor of -$19.9 million in Q1 2024.
  • Median Free Cash Flow over the past 5 years was -$8.8 million (2021), compared with a mean of -$8.2 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 951.03% in 2023 and later surged 213.13% in 2025.
  • Verrica Pharmaceuticals' Free Cash Flow stood at -$8.9 million in 2021, then soared by 43.82% to -$5.0 million in 2022, then tumbled by 193.51% to -$14.7 million in 2023, then dropped by 9.03% to -$16.1 million in 2024, then soared by 71.2% to -$4.6 million in 2025.
  • The last three reported values for Free Cash Flow were -$4.6 million (Q4 2025), $9.7 million (Q3 2025), and -$10.0 million (Q2 2025) per Business Quant data.